文献速递性腺与生殖内分泌

接受与未接受性腺切除术的跨性别女性血清睾酮与肾上腺雄激素水平变化

Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究纳入275例起始雌二醇与醋酸环丙孕酮治疗的跨性别女性,随访至2-4年,其中49.5%接受性腺切除术。结果显示治疗3个月后总睾酮、计算游离睾酮和雄烯二酮大幅下降后保持稳定,DHEA与DHEAS在1年时下降后不再变化;性腺切除及停用醋酸环丙孕酮后雄激素无进一步改变。

要点

  • 雌二醇联合醋酸环丙孕酮治疗3个月后总睾酮下降18.4 nmol/L(-97.1%),此后保持稳定。
  • DHEA与DHEAS在治疗1年时分别下降28.0%与20.1%,之后不再变化。
  • 性腺切除并停用醋酸环丙孕酮后,总睾酮、计算游离睾酮、DHEA、DHEAS和雄烯二酮较未手术者无进一步变化。

核心结论

  • 跨性别女性在初始下降后睾酮水平保持稳定,肾上腺雄激素在醋酸环丙孕酮与雌激素补充的第一年下降,性腺切除后不再变化,性腺切除并停用醋酸环丙孕酮后雄激素无变化,与临床症状的相关性尚待阐明。

研究设计与样本

  • 纳入275例起始雌二醇与醋酸环丙孕酮治疗的跨性别女性,在基线及3个月、12个月、2至4年随访,随访期间49.5%接受性腺切除术。
  • 采用液相色谱串联质谱法测定总睾酮、脱氢表雄酮、硫酸脱氢表雄酮和雄烯二酮。

主要发现

  • 治疗3个月后,平均总睾酮下降18.4 nmol/L(95% CI,-19.4至-17.4,P < 0.001,即-97.1%),计算游离睾酮下降383 pmol/L(95% CI,-405至-362,P < 0.001,即-98.3%),雄烯二酮下降1.2 nmol/L(95% CI,-1.4至-1.0,P < 0.001,即-36.5%),此后保持稳定。
  • 治疗1年后,脱氢表雄酮下降7.4 nmol/L(95% CI,-9.7至-5.1,即-28.0%),硫酸脱氢表雄酮下降1.8 µmol/L(95% CI,-2.2至-1.4,即-20.1%),此后不再变化。
  • 性腺切除后停用醋酸环丙孕酮,与未接受性腺切除者相比,总睾酮、计算游离睾酮、脱氢表雄酮、硫酸脱氢表雄酮和雄烯二酮均无进一步变化。

局限性

  • 与临床症状的相关性尚待阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Initiating feminizing gender-affirming hormone therapy (GAHT) in transgender women causes a steep decline in serum testosterone. It is unknown if testosterone concentrations change further and whether adrenal androgen levels change during feminizing GAHT and after gonadectomy. This limits clinical decision making in transgender women with symptoms attributed to GAHT or gonadectomy. METHODS: Transgender women (n = 275) initiating estradiol and cyproterone acetate (CPA) were included at baseline, and had follow-up visits after 3 months, 12 months, and 2 to 4 years. During follow-up, 49.5% of transgender women underwent a gonadectomy. Total testosterone (TT), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), and androstenedione (A4) were measured using liquid chromatography tandem mass spectrometry. RESULTS: After 3 months of GAHT, mean TT, calculated free testosterone (cFT), and A4 decreased by 18.4 nmol/L (95% CI, -19.4 to -17.4, P < 0.001 [ie, -97.1%]), 383 pmol/L (95% CI, -405 to -362, P < 0.001 [ie, -98.3%]), and 1.2 nmol/L (95% CI, -1.4 to -1.0, P < 0.001 [ie, -36.5%]), respectively, and remained stable thereafter. DHEA and DHEAS decreased by 7.4 nmol/L (95% CI, -9.7 to -5.1 [ie, -28.0%]) and 1.8 µmol/L (95% CI, -2.2 to -1.4 [ie, -20.1%]), respectively, after 1 year and did not change thereafter. After gonadectomy, CPA therapy is stopped, which induced no further change in TT, cFT, DHEA, DHEAS, and A4 compared with those who did not undergo gonadectomy. CONCLUSIONS: Our findings confirm that after an initial drop, testosterone levels in transgender women remain stable. Adrenal androgens decrease in the first year of CPA and estrogen supplementation and remain unchanged after gonadectomy. Androgens did not change after gonadectomy and cessation of CPA. Correlates with clinical symptoms remain to be elucidated.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Collet S, Gieles NC, Wiepjes CM, et al. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy. J Clin Endocrinol Metab. 2023. PMID: 36201493. doi:10.1210/clinem/dgac576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。